CorFlow Therapeutics Announces FDA Approval of the MOCA-II IDE Pivotal Trial to Validate a Novel Heart Attack Care Technology
BAAR, Switzerland — CorFlow Therapeutics AG (CorFlow), a pioneering company in the field of cardiac care targeting microvascular disease, today announced that the U.S. Food & Drug Administration (FDA) has approved the company's technology for investigational device exemption (IDE), which allows the pivotal clinical trial to begin at U.S. hospitals. CorFlow will now prepare these clinical trial sites to receive CorFlow systems, undergo training and begin enrolling patients being treated for heart attacks.
Article content
The IDE Pivotal Trial, MOCA-II, is intended to prospectively validate the diagnostic accuracy of the proprietary CorFlow CoFl system in determining the presence or absence of microvsacular obstruction (MVO) during a primary PCI procedure. The primary endpoint compares the CoFI diagnostic reading to a reference standard of diagnosis by a cardiac MRI scan. The trial is approved to enroll over 200 STEMI patients at prestigious research institutions in both the United States and Europe.
Article content
Article content
Having successfully completed the first-in-human MOCA-I trial in 2024, the MOCA-II study is the next critical step to bringing this unique technology into the hands of interventional cardiologists globally for the rapid diagnosis of MVO in heart attack patients. This in turn can enable new treatments and care pathways to the large MVO patient population with high rates of adverse clinical outcomes today. The CorFlow technology is designed to both diagnose MVO, plus serve as a localized drug delivery system for diagnostic and therapeutic agents, which is being researched independently.
Article content
According to the US government Centers for Disease Control and Prevention, someone has a heart attack every 30 seconds in the USA, with about 800,000 cases reported annually in the country. Incidence and prevalence are similarly high in Europe. More than half of STEMI heart attack patients are shown to have MVO, and previous research has demonstrated that the presence of MVO is a major driver of adverse events. Currently, there are no technologies approved to diagnose MVO during an acute coronary intervention, and there are no approved therapeutic devices that specifically address MVO in the United States or Europe. Heart attacks and related heart disease remains a leading cause of death and disability worldwide.
Article content
Paul Mead, CEO of CorFlow, said, 'The long history of interventional cardiology and heart attack care breakthroughs – going back over 100 years – is one of the great success stories of medical care progress, but the pioneers and luminaries of the field all agree that the work is unfinished. The majority of acute STEMI survivors have MVO, and current outcomes for these patients are shockingly poor. We aim to bring this issue to light and show you can do something about it. This milestone brings us all one step closer to delivering on the promise to improving care for these people where we know we can do better.'
Article content
MOCA-II is being led by world-renowned experts in heart attack care, Dr. Timothy Henry at The Christ Hospital in Cincinnati, Ohio (United States) and Professor Marco Valgimigli at Cardiocentro Ticino Institute, Lugano (Switzerland), who collectively have been published in over 1,000 peer-reviewed manuscripts in cardiovascular research.
Article content
Dr. Tim Henry said, 'As an interventional cardiologist involved for decades in managing and researching STEMI patients, I am excited to get going on this pivotal trial with technology that could make such a significant impact to the outcome of our patients. I believe strongly that knowing with high confidence who has MVO at the point of care during a primary PCI procedure can make an immediate difference in how we manage our patients.' Professor Valgimigli added, 'Having played a significant part in MOCA-I first in human trial, I am thrilled to see the second-generation technology now available for the pivotal trial and am looking forward to contributing further to the scientific understanding of MVO in real time. While the medical community has diverse opinions on how to treat these patients, there is no question that proper diagnosis is the first step we need. I am optimistic that getting the CorFlow technology approved for everyday use by our peer interventional cardiologists can help move the field forward.'
Article content
About CorFlow Therapeutics: Headquartered in Baar, Switzerland, with subsidiary operations in both Italy and the United States. The company is venture capital funded with an international VC firm syndicate, most recently with a Series B financing round announced in September 2024. CorFlow aspires to be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow anywhere in the human body where a critical need exists. Working in close partnership with scientists from the University of Bern, ETH Zurich and the University Hospital Zurich, in a collaboration funded by the Swiss Innovation Agency (Innosuisse), CorFlow continues to explore applications for the unique patented technology.
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
27 minutes ago
- CTV News
Rare ‘corpse plant' blooms at Austin Peay University drawing visitors
Austin Peay University is home to two extremely rare corpse plants, with fewer than 1,000 existing worldwide. (WTVF via CNN Newsource) CLARKSVILLE, Tennessee (WTVF) - A botanical rarity is drawing attention at Austin Peay University, where one of the world's most unusual plants is putting on a spectacular but brief show. Unlike its name, the corpse plant is very alive. But it earned its morbid nickname honestly. 'It's all going to look at smell like rotten flesh,' said Dr. Karen Meisch, Dean of the STEM College at Austin Peay University. Miesch explained that fewer than a thousand of these plants exist in the world today. 'This is the titan arum normally found or natively found in Indonesia on the island of Sumatra,' she said. The university houses two corpse plants. These plants take about seven to ten years to bloom, and when they do, the resulting flower only lasts a day or so. 'Athena's outer leaves dropped Sunday morning and they will typically bloom within 2 to 5 days,' Meisch said. Athena's bloom takes just two weeks to grow from a small sprout into a towering flower, and it won't come back for another two to five years. 'Eventually it will go back 100 percent into the soil and it will be there for about 3-4 months,' Meisch said. In between flowerings, the plant grows for nine-month periods, falls off, and continues the cycle. 'Even though it looks like a tree it is a single leaf,' Meisch said. The flower attracts beetles with its pungent smell when it blooms to pollinate. 'The beetles have to find another flower that's in bloom in that 24-hour period,' Meisch said. This rare bloom reminds us to treasure nature's fleeting wonders. By Kim Rafferty.
Globe and Mail
an hour ago
- Globe and Mail
Biden's former doctor requests delay of House panel testimony over patient privilege concerns
Former U.S. president Joe Biden's physician has asked to delay his testimony before the House oversight committee this week, citing the need for an agreement that will respect doctor-patient confidentiality rules as part of the investigation into Biden's health in office. Dr. Kevin O'Connor, who served as Biden's physician at the White House, requested a delay until the end of July or early August 'to reach an accommodation that will protect the very substantial privilege and confidentiality interests of Dr. O'Connor and former President Biden,' according to a letter from his lawyer sent to Rep. James Comer of Kentucky on Saturday. The Associated Press obtained a copy of the letter. A spokesperson for Oversight Republicans said the committee will follow the House's deposition guidelines, which allow for witnesses to assert privilege on a question-by-question basis, with the committee chair ruling on each claim. But O'Connor is not allowed, in the committee's view, to delay or decline a congressional subpoena due to concerns over questions about potentially privileged information. The back-and-forth is part of a broader struggle over the scope of the House Republican inquiry into Biden's age and mental fitness, with serious implications for both politics and policy. Republicans have also claimed that some policies carried out by the White House 'autopen' may be invalid if it is proven that Biden was mentally incapacitated for some part of his term. David Shribman: Biden's reputation has been besmirched – with parallels to Nixon's post-White House isolation Biden has strongly denied claims that he was not in a right state of mind at any point while in office, calling the claims 'ridiculous and false.' The House Oversight Committee first requested O'Connor testify before the committee last July, but the Biden White House blocked his testimony. Comer renewed his request in May and later subpoenaed the doctor in June. David Schertler, the attorney for O'Connor, in the letter said the committee is refusing to 'accommodate to any degree Dr. O'Connor's objections' over protecting privilege. He said the committee's decision was 'unprecedented' and 'alarming' and warned that it threatened broader principles around medical privacy. Scherlter said O'Connor could face 'serious consequences' for violating his obligations as a doctor, including losing his medical license. In a June subpoena of O'Connor, Comer said that claims of physician-patient privilege under the American Medical Association's code of ethics 'lack merit' because that code is not part of federal law. He said the committee's subpoena meets the AMA's own requirement that physicians must share a patient's medical information if 'legally compelled to disclose the information' or 'ordered to do so by legally constituted authority.' Comer has promised that the committee will make all its findings public in a report after the inquiry has finished. He has subpoenaed O'Connor and Anthony Bernal, former chief of staff to former first lady Jill Biden. The committee last month heard voluntary testimony from Neera Tanden, former director of Biden's domestic policy counsel. The committee has also requested the testimony of nearly a dozen former senior Biden aides, including former White House chiefs of staff Ron Klain and Jeff Zients; former senior advisers Mike Donilon and Anita Dunn; former deputy chief of staff Bruce Reed, former counselor to the president Steve Ricchetti, former deputy chief of staff Annie Tomasini and a former assistant to the president, Ashley Williams. The Trump White House has waived executive privilege, a principle that protects many communications between the president and staff from Congress and the courts, for almost 10 senior former Biden staffers. That move clears the way for those staffers to discuss their conversations with Biden while he was president. While the privilege can apply to former staffers, the decision of whether to waive it is decided by the sitting administration.
CTV News
2 hours ago
- CTV News
Biden's former doctor asks to delay testimony to House panel, citing patient privilege concerns
FILE - President Joe Biden walks along the Colonnade at the White House with his physician Kevin O'Connor, Aug. 28, 2023. (AP Photo/Manuel Balce Ceneta, File) WASHINGTON — Former U.S. President Joe Biden's physician has asked to delay his testimony before the House oversight committee this week, citing the need for an agreement that will respect doctor-patient confidentiality rules as part of the investigation into Biden's health in office. Dr. Kevin O'Connor, who served as Biden's physician at the White House, requested a delay until the end of July or early August 'to reach an accommodation that will protect the very substantial privilege and confidentiality interests of Dr. O'Connor and former President Biden,' according to a letter from his lawyer sent to Rep. James Comer of Kentucky on Saturday. The Associated Press obtained a copy of the letter. A spokesperson for Oversight Republicans said the committee will follow the House's deposition guidelines, which allow for witnesses to assert privilege on a question-by-question basis, with the committee chair ruling on each claim. But O'Connor is not allowed, in the committee's view, to delay or decline a congressional subpoena due to concerns over questions about potentially privileged information. The back-and-forth is part of a broader struggle over the scope of the House Republican inquiry into Biden's age and mental fitness, with serious implications for both politics and policy. Republicans have also claimed that some policies carried out by the White House 'autopen' may be invalid if it is proven that Biden was mentally incapacitated for some part of his term. Biden has strongly denied claims that he was not in a right state of mind at any point while in office, calling the claims 'ridiculous and false.' The House Oversight Committee first requested O'Connor testify before the committee last July, but the Biden White House blocked his testimony. Comer renewed his request in May and later subpoenaed the doctor in June. David Schertler, the attorney for O'Connor, in the letter said the committee is refusing to 'accommodate to any degree Dr. O'Connor's objections' over protecting privilege. He said the committee's decision was 'unprecedented' and 'alarming' and warned that it threatened broader principles around medical privacy. Scherlter said O'Connor could face 'serious consequences' for violating his obligations as a doctor, including losing his medical license. In a June subpoena of O'Connor, Comer said that claims of physician-patient privilege under the American Medical Association's code of ethics 'lack merit' because that code is not part of federal law. He said the committee's subpoena meets the AMA's own requirement that physicians must share a patient's medical information if 'legally compelled to disclose the information' or 'ordered to do so by legally constituted authority.' Comer has promised that the committee will make all its findings public in a report after the inquiry has finished. He has subpoenaed O'Connor and Anthony Bernal, former chief of staff to former first lady Jill Biden. The committee last month heard voluntary testimony from Neera Tanden, former director of Biden's domestic policy counsel. The committee has also requested the testimony of nearly a dozen former senior Biden aides, including former White House chiefs of staff Ron Klain and Jeff Zients; former senior advisers Mike Donilon and Anita Dunn; former deputy chief of staff Bruce Reed, former counselor to the president Steve Ricchetti, former deputy chief of staff Annie Tomasini and a former assistant to the president, Ashley Williams. The Trump White House has waived executive privilege, a principle that protects many communications between the president and staff from Congress and the courts, for almost 10 senior former Biden staffers. That move clears the way for those staffers to discuss their conversations with Biden while he was president. While the privilege can apply to former staffers, the decision of whether to waive it is decided by the sitting administration. Matt Brown And Michelle L. Price, The Associated Press
